# To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

> **NCT05065463** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 3 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** AZD8233

## Key facts

- **NCT ID:** NCT05065463
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-10
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** A decision has been taken to discontinue the development of AZD8233 (PCSK9-ASO for sc administration) due to low likelihood of demonstrating a benefit significantly above the current standard of care for patients with high-risk hypercholesterolemia.
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065463, "To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05065463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*